Partner Headlines - AMGN

  1. Stocks Mixed Despite Better-Than-Expected GDP

    Benzinga
  2. Amgen Price Target Raised by Various Analysts

    Benzinga
  3. Amgen Restructuring Plan, Q2 Earnings Send Stock Up

    IBD
  4. Quarterly “Beats”: Bah, Here Are Real Growers

    YCharts
  5. Amgen To Slash Workforce

    IBD
  6. Indexes End Lower As Russia Sanctions Hit Stocks

    IBD
  7. Stock Futures Show Some Muscle; Merck, Cognex Rising

    IBD
  8. Earnings Scheduled For July 29, 2014

    Benzinga
  9. Top 5 Earnings Reports To Watch After The Close Tue.

    IBD
  10. Pfizer, Merck, Amgen Near Q2 Earnings Reports

    IBD
  11. Benzinga Weekly Preview: FOMC In Focus, As Earnings Season Progresses

    Benzinga
  12. US Stock Futures Drop Ahead Of Durable Goods Orders Data

    Benzinga
  13. Biotech Enters Reporting Season With Large Caps Central To Sector ...

    Benzinga
  14. UPDATE: Amgen Announces Positive Phase 3 Results For AMG 416 ...

    Benzinga
  15. Yellen Swats Down Biotech, Social Media Stocks

    FoxBusiness
  16. Morgan Stanley Issues 2015 'Vintage Values' Stock List

    Benzinga
  17. Celgene Drug Otezla Fails Trial, But Street Sanguine

    IBD
  18. Alexion Pharma Looks To Life Beyond Its Blockbuster

    IBD
  19. Bind Therapeutics

    IBD
  20. Citi Sees Plenty Of Q2 Earnings Beats Ahead In Biotech Sector

    Benzinga
  21. Bind Therapeutics Down After Losing Amgen Partnership

    IBD
  22. Dow Hits 17,000 On Jobs Report; Walgreen Same-Store-Sales Surge ...

    Benzinga
  23. Morning Market Losers

    Benzinga
  24. Top 4 Stocks In The Biotechnology Industry With The Highest EPS

    Benzinga
  25. Benzinga's M&A Chatter for Monday June 16, 2014

    Benzinga
  26. InterMune Up On Bullish View Of U.S. Esbriet Launch

    IBD
  27. UPDATE: Morgan Stanley Reiterates On Amgen On New CFO

    Benzinga
  28. Teva Acquiring Labrys Biologics For Migraine Drug

    IBD
  29. UPDATE: Morgan Stanley Reiterates On Amgen Following AMAGINE-1 ...

    Benzinga
  30. Gulf Resources (GURE) Impressive Performance, Amgen (AMGN) and ...

    GuruFocus
  31. Amgen

    IBD
  32. Top 4 NASDAQ Stocks In The Biotechnology Industry With The Highest ...

    Benzinga
  33. Amgen Blazed Biotech Trail, Earned 165,233% Reward

    IBD
  34. Market Wrap For April 23: S&P 500 Ends Winning Streak, Apple ...

    Benzinga
  35. Stocks End Six-Day Win Streak As Techs Sell Off

    IBD
  36. Stock Futures Mixed And Busy; Illumina Rockets, Cree Tumbles

    IBD
  37. #PreMarket Primer: Wednesday, April 23: Data From China Takes ...

    Benzinga
  38. AMGEN

    IBD
  39. Gilead Soars As Hep C Drug Shatters Views; Amgen Misses

    IBD
  40. Rallying Ahead of Earnings

    FoxBusiness
  41. Nasdaq, S&P 500 On Track For Sixth Straight Gain

    IBD
  42. Amgen Slumps After 1Q Earnings Miss

    FoxBusiness
  43. Stocks Power Out Early Gains; Allergan Leads Drug-Maker Surge

    IBD
  44. Earnings Scheduled For April 22, 2014

    Benzinga
  45. Biohazard? Gilead Leads 5 Big-Cap Biotech Earnings

    IBD
  46. Short Interest Rises As Biotechs Fall (AMGN, CELG, DNDN)

    Benzinga
  47. Pfizer Breast-Cancer Drug Scores, But Street Cautious

    IBD
  48. UPDATE: Amgen Spiking Lower 1.5%, Says Primary Endpoint of Durable ...

    Benzinga
  49. Amgen, GSK End Marketing Pact for Osteoporosis Drug

    FoxBusiness
  50. Cholesterol drug meets goal

    IBD
  51. Trial Results Lift Drug Sector

    IBD
  52. Amgen Stock Gets Bump Up On Cholesterol Drug Data

    IBD
  53. Jefferies Raises PT On Amgen, Pricing Pressure Factored IN

    Benzinga
  54. Gilead Adds To Biotech Woes

    IBD
  55. Gilead Sovaldi Scrips Falter As Biotechs Keep Falling

    IBD
  56. New Cholesterol Fighters To Take Center Stage At ACC

    IBD
  57. Market Wrap For March 27: Markets Lower Following Mixed Economic ...

    Benzinga
  58. Biotech ETFs Come Back Down To Earth

    Benzinga
  59. Morgan Stanley's Top Biotech Pick is Biogen

    Benzinga
  60. BIOGEN IDEC

    IBD
  61. Have We Seen The Top Of The Market?

    Benzinga
  62. Market Wrap For March 18: Markets Positive Despite Crimea Concerns

    Benzinga
  63. Amgen up on drug trial result

    IBD
  64. Amgen's PCSK9 Scores Against Genetic High Cholesterol

    IBD
  65. US Stock Futures Edge Lower Ahead Of Wholesale Trade Data

    Benzinga
  66. Bayer, Onyx Report Primary Endpoint of Phase 3 Study Results ...

    Benzinga
  67. Regeneron Cholesterol-Drug Worries Ding Stock

    IBD
  68. Biogen Idec Keeps Momentum Going With MS Drug Tecfidera

    IBD
  69. Insys Set To Report Q4 Earnings With Stock Surging

    IBD
  70. Why Stock Shakeouts Can Be Scary, Yet Constructive

    IBD
  71. Amgen, BioMarin Lead Biotech Short Interest Trend (AMGN, BIIB, ...

    Benzinga
  72. Novartis Vs. Everyone: Biologic Knockoffs

    YCharts
  73. Revenue Growth: Focus On Healthcare Stocks

    YCharts
  74. France's Biosimilar Substitution May Lead to Erosion of Amgen

    Benzinga
  75. Why Mr. Cautious Is 82% Invested In Stocks

    YCharts
  76. Illumina, Alexion Lead 4 Big Caps Drawing Big Buyers

    IBD
  77. You Can No Longer Ignore Biotech

    GuruFocus
  78. Merck soars on cancer deal

    IBD
  79. Merck Q4 Misses, But Cancer Deals Ignite Stock

    IBD
  80. Merck Misses Estimates in 4Q; Plans Increased Focus on Cancer

    FoxBusiness
  81. Amgen Announces Positive Top-Line Results From Phase 3 RUTHERFORD-2 ...

    Benzinga
  82. Pfizer, Amgen Earnings Beat

    IBD
  83. Amgen Announces Positive Top-Line Results From Phase 3 LAPLACE-2 ...

    Benzinga
  84. Earnings Scheduled For January 28, 2014

    Benzinga
  85. Benzinga Weekly Preview: Tech Sector To Steal The Spotlight

    Benzinga
  86. Amgen

    IBD
  87. Amgen Announces Positive Top-Line Results From Phase 3 GAUSS-2 ...

    Benzinga
  88. Drugmaker Merck Tries To Jump-Start Slow Growth

    IBD
  89. Illumina, Jazz Among 5 Young Guns Hitting New Highs

    IBD
  90. Illumina Details Its Strategy; Stock Jumps Again

    IBD
  91. Market Wrap For January 16: Markets End Two Day Winning Streak

    Benzinga
  92. ILLUMINA

    IBD
  93. Drug Buyouts On The Rise -- But Buyers Changing

    IBD
  94. Amgen, Mass General, Broad Institute Collaborate on New Drugs ...

    Benzinga
  95. Biotech Stocks Back On Top, Led By Biogen, Alexion

    IBD
  96. Mario Gabelli Comments on Amgen Inc.

    GuruFocus
  97. Amgen drug gets high marks

    IBD
  98. Amgen Announces Romosozumab Phase 2 Data Published In NEJM Show ...

    Benzinga
  99. Biologic Makers Thwart Generics: Winning Stocks

    YCharts
  100. Rising Short Interest In Pharmacyclics, Other Biotechs (AMGN, ...

    Benzinga
Trading Center